In December 2025, Eli Lilly released Phase 3 results for retatrutide (a triple-agonist therapy) GLP-1, GIP, glucagon
5,6,7 GLP-1 is a peptide produced by the cleavage of proglucagon, mainly synthesized in the intestinal mucosal L-cells, pancreatic islet -cells, and neurons in the nucleus of the solitary tract
The data is the third late-stage result to date on retatrutide, which succeeded in a diabetes trial earlier this year and cleared a smaller study on patients with obesity and a type of knee arthritis in December
Similar content being viewed by others Article Cardiovascular disorders (CVDs) are the leading cause of adult mortality and morbidity worldwide, accounting for 17 million deaths (30% of all deaths) in 2008 [1]
While nausea is common with this medication, its important to note any other symptoms, as they might indicate pancreatitis
The 7025/65 grey formulation is a blend of a synthetic polyisoprene and a bromobutyl and is a well-known formulation used for multiple approved drugs in the pharmaceutical market
